Table 4 Summary of findings for the review’s main comparison
SMT with or without usual care compared to (least active) control for the treatment of migraines | |||||
|---|---|---|---|---|---|
Patient or population: migraineurs (all types) Setting: secondary care Intervention: SMT (with or without usual care) Comparison: (least active) control | |||||
Outcomes | No. of participants (studies) Follow-up | Certainty of the evidence (GRADE) | Relative effect (95% CI) | Anticipated absolute effects | |
Risk with (least active) control | Risk difference with SMT | ||||
Migraine days post-treatment | 472 (4 RCTs) | ⨁◯◯◯ Very lowa,b,c | – | – | SMD 0.24 lower (0.47 lower to 0.02 lower) |
Migraine duration post-treatment | 312 (4 RCTs) | ⨁◯◯◯ Very lowa,b,c | – | – | SMD 0.11 lower (0.33 lower to 0.12 higher) |
Intensity/severity post-treatment: measured with VAS scales | 509 (6 RCTs) | ⨁◯◯◯ Very lowa,b,c,d | – | – | SMD 0.22 SD lower (0.65 lower to 0.21 higher) |
Disability: measured with MIDAS | 234 (3 RCTs) | ⨁◯◯◯ Very lowa,b,c | – | – | SMD 0.27 lower (0.54 lower to 0.01 lower) |
Emotional QOL: measured with SF-36 | 111 (2 RCTs) | ⨁◯◯◯ Very lowa,b,e | – | – | SMD 14.47 lower (31.61 lower to 2.68 higher) |
Adverse effects | 764 (2 RCTs) | ⨁◯◯◯ Very lowa,b,c,d | RR 2.06 (1.24 to 3.41) | 113 per 1000 | 208 more per 1000 (102 more to 368 more) |